It has been a unique time line that over a very brief time demonstrates the rather drastic changes in our field. This talk will review front row observations belonging to those changes. The discussion will begin with traditional chemotherapy (outcomes and effects), review a similar journey through targeted therapy and now more recently immunotherapy . The talk will also propose where future therapy is headed as well as the major barriers it will likely face (scientific, social, financial, and political, etc)
1. To highlight progress (and failures) that have led to overall change in cancer care
2. Review the science belonging to those changes and how that science emerged
|Cancer Chemotherapy (2.00 MB)||36 Pages||Available after Purchase|
Dr. Balaban is originally from the Pittsburgh, PA area.He is a graduate of the University of Pittsburgh (1973) and the Philadelphia College of Osteopathic Medicine (1977). He would do his internship year at Detroit Osteopathic Hospital and Bi-County Community Hospital. Following that year, Dr. Balaban did an Internal Medicine residency in his hometown at Allegheny General Hospital. He began his career in Hematology and Medical Oncology with fellowship training at University of Texas Southwester in Dallas, Texas. He would remain on the faculty staff at UT Southwestern until 1994. Dr. Balaban subsequently relocated to community practice in Pennsylvania first in an independent practice and then as part of the University of Pittsburgh Medical Center network. He is the Medical Director of a community oncology practice in State College, PA and is on the faculty as Professor of Medicine at the Penn State Cancer Institute and Penn State College of Medicine.
Dr. Balaban is deeply involved in Medical Oncology serving on several boards and committees within American Society of Clinical Oncology.He has published extensively in the oncologic literature including a number of widely referenced treatment guidelines pertinent to the practice of Medical Oncology. He also serves on the editorial board of the Journal of Oncology Practice. Dr. Balaban is devoted to health policy issues affecting hematology/oncology as well as the overall medical community. He currently serves on the Board of Trustees of the Pennsylvania Medical Society and represents Medical Oncology at the AMA House of Delegates. He is a frequent visitor/advocate on Capitol Hill for ongoing federal issues as well as state-related medical practice issues that may be affected by state legislation in Harrisburg, PA.
Please wait ...